• Je něco špatně v tomto záznamu ?

Usage and impact of patient-reported outcomes in epilepsy

K. Vonck, A. Biraben, M. Bosak, PJ. Jennum, VK. Kimiskidis, P. Marusic, JW. Mitchell, LN. Ferreira, M. Ondrušová, A. Pana, U. Persson, TJ. von Oertzen, S. Lattanzi

. 2023 ; 13 (12) : e3342. [pub] 20231123

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000341

BACKGROUND: The use of patient-reported outcomes (PRO) in clinical practice is gaining increasing attention. This study aimed to provide a critical assessment of the current state-of-the-art and beliefs about the use of PRO in the management of people with epilepsy across some European countries. METHODS: Structured interviews were conducted with European experts to collect insights about (I) the personal experience with PRO; (II) the value and impact of PRO in the decision-making process at the national level; and (III) the interest for and use of PRO by national health authorities. RESULTS: Nine neurologists (Austria, Belgium, Czechia, Denmark, France, Greece, Italy, Poland, and United Kingdom), three health economists (Portugal, Romania, and Sweden), and one epidemiologist (Slovakia) participated. They all stated that PRO are collected at their own countries in the context of clinical trials and/or specific projects. During everyday clinical practice, PRO are collected routinely/almost routinely in Austria and Sweden and only at the discretion of the treating physicians in Czechia, Denmark, France, Greece, and Portugal. There was complete consensus about the favorable impact that the PRO can have in terms of clinical outcomes, healthcare resources utilization, and general patient satisfaction. Only participants from Portugal and Sweden answered that the PRO are perceived as very important by the National Health Authorities of their respective countries. CONCLUSIONS: Differences exist in attitudes and perspectives about PRO in epilepsy across Europe. An active plan is warranted to harmonize the measurement of PRO and ensure they can be relevant to people with epilepsy and health services.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000341
003      
CZ-PrNML
005      
20240213093123.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/brb3.3342 $2 doi
035    __
$a (PubMed)37997564
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vonck, Kristl $u Department of Neurology, 4Brain, Ghent University Hospital, Gent, Belgium
245    10
$a Usage and impact of patient-reported outcomes in epilepsy / $c K. Vonck, A. Biraben, M. Bosak, PJ. Jennum, VK. Kimiskidis, P. Marusic, JW. Mitchell, LN. Ferreira, M. Ondrušová, A. Pana, U. Persson, TJ. von Oertzen, S. Lattanzi
520    9_
$a BACKGROUND: The use of patient-reported outcomes (PRO) in clinical practice is gaining increasing attention. This study aimed to provide a critical assessment of the current state-of-the-art and beliefs about the use of PRO in the management of people with epilepsy across some European countries. METHODS: Structured interviews were conducted with European experts to collect insights about (I) the personal experience with PRO; (II) the value and impact of PRO in the decision-making process at the national level; and (III) the interest for and use of PRO by national health authorities. RESULTS: Nine neurologists (Austria, Belgium, Czechia, Denmark, France, Greece, Italy, Poland, and United Kingdom), three health economists (Portugal, Romania, and Sweden), and one epidemiologist (Slovakia) participated. They all stated that PRO are collected at their own countries in the context of clinical trials and/or specific projects. During everyday clinical practice, PRO are collected routinely/almost routinely in Austria and Sweden and only at the discretion of the treating physicians in Czechia, Denmark, France, Greece, and Portugal. There was complete consensus about the favorable impact that the PRO can have in terms of clinical outcomes, healthcare resources utilization, and general patient satisfaction. Only participants from Portugal and Sweden answered that the PRO are perceived as very important by the National Health Authorities of their respective countries. CONCLUSIONS: Differences exist in attitudes and perspectives about PRO in epilepsy across Europe. An active plan is warranted to harmonize the measurement of PRO and ensure they can be relevant to people with epilepsy and health services.
650    _2
$a lidé $7 D006801
650    12
$a hodnocení výsledků péče pacientem $7 D000071066
650    12
$a epilepsie $x terapie $7 D004827
651    _2
$a Evropa $7 D005060
651    _2
$a Itálie $7 D007558
651    _2
$a Polsko $7 D011044
655    _2
$a časopisecké články $7 D016428
700    1_
$a Biraben, Arnaud $u Unité d'épileptologie, CHU Pontchaillou Rennes, Rennes, France
700    1_
$a Bosak, Magdalena $u Department of Neurology, Medical College, Jagiellonian University, Krakow, Poland
700    1_
$a Jennum, Poul Jørgen $u Department of Clinical Neurophysiology, Danish Center for Sleep Medicine, Rigshospitalet, Denmark
700    1_
$a Kimiskidis, Vasilios K $u First Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece $1 https://orcid.org/0000000233353019
700    1_
$a Marusic, Petr $u Department of Neurology, Second Faculty of Medicine and Motol University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Mitchell, James W $u Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
700    1_
$a Ferreira, Lara N $u Universidade do Algarve-ESGHT, Faro, Portugal $u Centre for Health Studies and Research of the University of Coimbra (CEISUC), Centre for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal $u Research Centre for Tourism, Sustainability and Well-Being (CinTurs), Universidade do Algarve, Faro, Portugal $1 https://orcid.org/0000000323787750
700    1_
$a Ondrušová, Martina $u Department of Epidemiology and Biostatistics, Pharm-In, Ltd., Bratislava, Slovakia $u Faculty of Public Health, Slovak Medical University, Bratislava, Slovakia
700    1_
$a Pana, Adrian $u School of Public Health, Babes Bolyai University Cluj Napoca, Center for Health Outcomes & Evaluation, Cluj-Napoca, Romania
700    1_
$a Persson, Ulf $u The Swedish Institute for Health Economics, Lund, Sweden
700    1_
$a von Oertzen, Tim J $u Center for Medicine of the Elderly, Kepler University Hospital, Johannes Kepler University, Linz, Austria
700    1_
$a Lattanzi, Simona $u Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy
773    0_
$w MED00188000 $t Brain and behavior $x 2162-3279 $g Roč. 13, č. 12 (2023), s. e3342
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37997564 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093120 $b ABA008
999    __
$a ok $b bmc $g 2049169 $s 1210035
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 12 $d e3342 $e 20231123 $i 2162-3279 $m Brain and behavior $n Brain Behav $x MED00188000
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace